Fig. 12.

Schematic diagram showing the effects of a bone-forming agent on the relative fracture risk reduction (RRR) compared with placebo. In scenario A, treatment with a bone-forming agent induces a marked effect on fracture risk over an 18 months exposure compared with placebo. On stopping the bone-forming agent, the effect on fracture wanes off over a similar time interval of 18 months. In scenario C, placebo group remains untreated, whereas the group treated with a bone-forming agent is transitioned to an inhibitor of bone turnover, which maintains the efficacy up to 4 years. In scenario B, both the treatment and the placebo groups are treated after the exposure with an inhibitor of bone turnover [270]. With kind permission from Springer Science and Business Media